Mutaz Tabbaa, MD
Neurology · Panama City, FLNPI 1912198573
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $150 of the $150 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Jazz Pharmaceuticals Inc.. That places this record below the midpoint for neurology clinicians in FL, where the typical reported total is $1,698.
Across 1 payment — averaging $150.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$150
Across 6 payments — averaging $14,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB Biosciences Inc.$57K
- Boehringer Ingelheim$31K
- Boehringer Ingelheim RCV GmbH & Co KG$34
What the payments were for
- Consulting fees$150100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$150 in reported general payments places this provider in the 20th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VimpatLacosamide | 24 | $26,858 |
| TopamaxTopiramate | 12 | $25,304 |
| Keppra XrLevetiracetam | 12 | $25,267 |
| MyrbetriqMirabegron | 16 | $14,091 |
| Memantine Hcl | 406 | $13,808 |
| Galantamine ErGalantamine Hbr | 133 | $12,892 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $11,718 |
| LamictalLamotrigine | 12 | $8,640 |
| Felbamate | 13 | $8,123 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 284 | $7,210 |
| Primidone | 221 | $6,945 |
| Donepezil Hcl | 497 | $6,742 |
| Levetiracetam | 187 | $6,735 |
| Oxcarbazepine | 69 | $5,438 |
| Mirtazapine | 215 | $5,263 |
Paid to pharmacies, not to this prescriber.
Other neurology in Panama City
- Khurram NazirPanama City$193K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.